ALVR down 53% halted three of its late-stage clinical trials following recommendations from independent data monitors and will review strategic alternatives, including a potential sale.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.